Eli Lilly beats on quarterly profit, hikes full-year guidance on strong
sales of Zepbound, Mounjaro
Related Articles
-
Eli Lilly Jumps On Strong Earnings, Guidance As Zepbound Sales Beat
Eli Lilly (LLY) jumped early Tuesday after the pharma behemoth reported adjusted earnings of $2.58 per share on $8.77 billion in...
-
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its forecast for 2024 well beyond analyst expectations after sales of Mounjaro more than tripled in the year’s first quarter. Lilly said it was still dealing with supply issues, with strong demand for both drugs outpacing its production hikes. But the company expects its most significant increases to occur in...
-
Inside 9-1-1′s Wildest Wedding Surprises, From [Spoiler]’s Shocking Return to Buck’s Accidental Outing
Kenneth Choi breaks down Maddie and Chimney's wedding on '9-1-1.' Here's his take on Season 7 Episode 6.